A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics
Léonie Ferrer, Matteo Giaj Levra, Marie Brevet et al. · Journal of Thoracic Oncology · 2018
Cited by 158 works. doi:10.1016/j.jtho.2018.08.2028 Open-access PDF
Authors
- Léonie Ferrer
- Matteo Giaj Levra
- Marie Brevet
- Martine Antoine
- Julien Mazières
- Giulio Rossi
- Rita Chiari
- Virginie Westeel
- M. Poudenx
- Jacques Letreut
- R. Gervais
- Giorgia Amira Osman
- Nicolas Girard
- Anne‐Claire Toffart
- Silvia Novello
- Denis Moro‐Sibilot
References
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
- Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
- Small-Cell Carcinoma in the Setting of Pulmonary Adenocarcinoma: New Insights in the Era of Molecular Pathology
- Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib
- Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma
- Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: A retrospective study of 300 patients